The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells

Biomedicine and Pharmacotherapy

Volumn 70, Issue C, 2015, Pages 41-45

  Liu, Fengtao ^a   Si, Yanmin ^a   Liu, Guangchao ^a   Li, Shulian ^a   Zhang, Jun ^a   Ma, Yuanfang ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Antibody; Apoptosis; Cancer cell; DR5; Tetravalent

Indexed keywords

DEATH RECEPTOR 5 ANTIBODY; HUMAN SERUM ALBUMIN; PROTEIN P53; RECEPTOR ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SURFACE; CELL SURVIVAL; CELL VOLUME; CONTROLLED STUDY; CYTOTOXICITY; ESOPHAGEAL CANCER CELL LINE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; JURKAT CELL LINE; MTT ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; ESOPHAGUS TUMOR; IMMUNOLOGY; LYMPHATIC LEUKEMIA; METABOLISM; TUMOR CELL LINE;

ANTIBODIES; APOPTOSIS; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; JURKAT CELLS; LEUKEMIA, LYMPHOID; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84927560605     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.024     Document Type: Article

References (24)

1. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
2. Gura T. How TRAIL eliminates cancer cells, but not normal cells. Science 1997, 277:768.
3. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821.
4. Schneider P., Thome M., Burns K., Bodmer J.L., Hofmann K., Kataoka T., et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997, 7:831-836.
5. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997, 7:821-830.
6. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000, 2:241-243.
7. Safa A.R. c-FLIP, a master anti-apoptotic regulator. Exp Oncol 2012, 34:176-184.
8. Kim H., Samuel S.L., Zhai G., Rana S., Taylor M., Umphrey H.R., et al. Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biol Ther 2014, 15:1053-1060.
9. Griffith T.S., Rauch C.T., Smolak P.J., Waugh J.Y., Boiani N., Lynch D.H., et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999, 162:2597-2605.
10. Chuntharapai A., Dodge K., Grimmer K., Schroeder K., Marsters S.A., Koeppen H., et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001, 166:4891-4898.
11. Berg D., Lehne M., Muller N., Munkel S., Sebald W., Pfizenmaier K., et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007, 14:2021-2034.
12. Poh T.W., Huang S., Hirpara J.L., Pervaiz S. LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ 2007, 14:1813-1825.
13. Liu R.M., Wang M.L., Ji Z.J., Ma Y.F. Clone of the anti-DR5 antibody variable sequence by phage surface display. J Henan Univ 2011, 30:51-53.
14. Dugaiczyk A., Law S.W., Dennison O.E. Nucleotide sequence and the encoded amino acids of human serum albumin mRNA. Proc Natl Acad Sci U S A 1982, 79:71-75.
15. Liu M., Wang X., Yin C., Zhang Z., Lin Q., Zhen Y., et al. Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb. Biochem J 2007, 406:237-246.
16. Jeffrey P.D., Gorina S., Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995, 267:1498-1502.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferationand cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
18. Ning X., Shu J., Du Y., Ben Q., Li Z. Therapeutic strategies targeting cancer stem cells. Cancer Biol Ther 2013, 14:295-303.
19. Mérino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006, 26:7046-7055.
20. Nicole M.H., Edwin D.H., Ming L., Nicole M.M., Gunter J.H., Reto S., et al. CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors. J Immunol 2010, 185:532-541.
21. Motoki K1, Mori E., Matsumoto A., Thomas M., Tomura T., Humphreys R., et al. Enhanced apoptosis and tumor regression induced by a directly agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005, 11:3126-3135.
22. Gieffers C1, Kluge M., Merz C., Sykora J., Thiemann M., Schaal R., et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic anti-tumor efficacy independent of cross-linking via Fcγ receptors. Mol Cancer Ther 2013, 12:2735-2747.
23. Pavet V., Beyrath J., Pardin C., Morizot A., Lechner M.C., Briand J.P., et al. Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity. Cancer Res 2010, 70:1101-1110.
24. Bi H.L., Du Y.W., Wang X.Y., Li S.L., Wamg J., Liu G.C., et al. The study on the apoptosis mechanism of the Jurkat cell induced by cross-linking anti-DR5 antibody YM366 EC. Curr Immunol 2007, 23:789-797.